Company intelligence / Profile preview
Cincera Therapeutics
Melbourne, Victoria, Australiacinceratx.com ↗
- Ownership
- Private
- Employees
- ~3
- Development stage
- Other
01
Overview
Cincera Therapeutics develops potent, orally available small molecule inhibitors targeting a key enzyme in lipid metabolism. Their approach reduces fibrosis and inflammation at lower doses than current therapies by modulating the quality rather than the quantity of bioactive lipids. Preclinical data show strong anti-inflammatory/anti-fibrotic effects with potential for single-agent or combination use in metabolic diseases such as NASH, CKD, and others.
- Therapeutic areas
- Metabolic DisordersOncologyImmunologyGastroenterologyNephrology
- Modalities
- Small molecules (orally available inhibitors)
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
Beyond the preview
Go deeper on Cincera Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Cincera Therapeutics.